| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The compound's targets are not fully defined but are associated with pathways involved in promoting blood circulation, improving myocardial ischemia, and exerting weak inhibitory activity against H9C2 cardiomyocytes.
|
|---|---|
| ln Vitro |
In vitro, 20(R)-Notoginsenoside R2 exhibits weak inhibitory activity against H9C2 cells. It is also studied for its potential to protect cells from ischemic injury and modulate inflammatory responses.
|
| ln Vivo |
In vivo, this saponin promotes blood circulation and improves myocardial ischemia in animal models. It has been studied for therapeutic effects in cardiovascular diseases and may offer neuroprotection in models of neurodegeneration.
|
| Enzyme Assay |
Receptor binding assays are not well established for this compound. Studies typically use cell-based functional assays to assess its biological activity, such as measuring cell viability or markers of oxidative stress in cultured cells.
|
| Cell Assay |
H9C2 rat cardiomyoblast cells are cultured and treated with 20(R)-Notoginsenoside R2 at various concentrations. Cell viability is measured using MTT or CCK-8 assays to assess its cytotoxic or protective effects.
|
| Animal Protocol |
Myocardial ischemia models in rodents are used to evaluate cardioprotective effects. The compound is administered via oral gavage or intravenous injection, and parameters such as infarct size, ECG changes, and cardiac enzyme levels are measured.
|
| ADME/Pharmacokinetics |
Pharmacokinetic studies are limited. As a saponin, it likely has poor oral bioavailability due to high molecular weight and poor membrane permeability. It is typically administered parenterally in research settings.
|
| Toxicity/Toxicokinetics |
Specific toxicity data are limited. Saponins can cause hemolysis and gastrointestinal irritation at high doses. The compound is considered relatively safe at pharmacological doses based on its traditional use.
|
| References | |
| Additional Infomation |
20(R)-Notoginsenoside R2 is a research-grade natural product with no clinical trial or regulatory approval status. It is used primarily as a reference standard and in pharmacological studies of cardiovascular and neurodegenerative diseases.
|
| Molecular Formula |
C41H70O13
|
|---|---|
| Molecular Weight |
770.9867
|
| Exact Mass |
770.481
|
| CAS # |
948046-15-9
|
| PubChem CID |
16757287
|
| Appearance |
White to light yellow solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
878.7±65.0 °C at 760 mmHg
|
| Flash Point |
485.2±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.597
|
| Source |
Originated from plants: Araliaceae Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow
|
| LogP |
6.45
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
54
|
| Complexity |
1360
|
| Defined Atom Stereocenter Count |
20
|
| SMILES |
C[C@@]12C[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3OC[C@@H](O)[C@H](O)[C@H]3O)[C@H]3C([C@H](CC[C@]3(C)[C@H]1C[C@@H](O)[C@@H]1[C@H](CC[C@@]21C)[C@@](O)(C)CC/C=C(\C)/C)O)(C)C
|
| InChi Key |
FNIRVWPHRMMRQI-RFMRREALSA-N
|
| InChi Code |
InChI=1S/C41H70O13/c1-20(2)10-9-13-41(8,50)21-11-15-39(6)28(21)22(43)16-26-38(5)14-12-27(45)37(3,4)34(38)24(17-40(26,39)7)52-36-33(31(48)30(47)25(18-42)53-36)54-35-32(49)29(46)23(44)19-51-35/h10,21-36,42-50H,9,11-19H2,1-8H3/t21-,22+,23+,24-,25+,26+,27-,28-,29-,30+,31-,32+,33+,34-,35-,36+,38+,39+,40+,41+/m0/s1
|
| Chemical Name |
(2S,3R,4S,5R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-17-[(2R)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~129.7 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.24 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.24 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2970 mL | 6.4852 mL | 12.9703 mL | |
| 5 mM | 0.2594 mL | 1.2970 mL | 2.5941 mL | |
| 10 mM | 0.1297 mL | 0.6485 mL | 1.2970 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
